Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Choline Quantification in Breast Cancer by MRS

This study has been withdrawn prior to enrollment.
(We chose to use an exsisting NMR pulse sequence already established and available at the hospital.)
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology Identifier:
First received: September 16, 2005
Last updated: October 30, 2013
Last verified: October 2013

Choline has been found in increased concentration in breast cancer patients. Hypothesis: The choline signal as observed by MRS is sensitive to treatment, and a positive response to treatment will give a reduction in choline concentration.

The purpose of this study is to establish methods for quantification of choline in breast cancer by MRS

Breast Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Choline Quantification in Breast Cancer by MRS

Resource links provided by NLM:

Further study details as provided by Norwegian University of Science and Technology:

Enrollment: 0
Study Start Date: November 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Detailed Description:
  1. Establishment of new MRS sequence for choline quantification of choline. This sequence is choline-selective, and signals from water and lipids are suppressed simultaneously.
  2. Compare to different methods for choline quantification. The first method is quantification through an external phantom standard, containing a known concentration of choline. The other method is based on the utilisation of internal water signal as a reference.

Both calculations can be performed from the same MR exam. Ten patients will be included in the study.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
breast cancer

Inclusion Criteria:

  • breast cancer

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00201487

Sponsors and Collaborators
Norwegian University of Science and Technology
The Norwegian Women´s Public Health Association
Principal Investigator: Tone Bathen, PhD NTNU, Faculty of medicine,
  More Information

Responsible Party: Norwegian University of Science and Technology Identifier: NCT00201487     History of Changes
Other Study ID Numbers: 11870
Study First Received: September 16, 2005
Last Updated: October 30, 2013

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Lipotropic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Lipid Regulating Agents
Nootropic Agents processed this record on May 25, 2017